Table 1.
Subject characteristics
| Clinical characteristic | Control | Ultraflltration | Total | P |
|---|---|---|---|---|
| Number | 39 (35) | 74 (65) | 113 (100) | |
| Age, years | 55.5 ± 11.5 | 54.3 ± 12.6 | 54.7 ± 12.2 | 0.6 |
| Male | 31 (79) | 48 (65) | 79 (70) | 0.1 |
| Race | 0.8 | |||
| White | 3 (8) | 9 (12) | 12 (11) | |
| Black | 35 (90) | 63 (85) | 98 (87) | |
| Other | 1 (3) | 2 (3) | 3 (3) | |
| Pre-HD seated BP, mm Hg | 157.8 ± 15.8/87.0 ± 12.8 | 158.5 ± 16.2/85.5 ± 10.5 | 158.3 ± 16.0/86.0 ± 11.3 | 0.8/0.5 |
| Post-HD seated SBP, mm Hg | 141.5 ± 19.9/77.1 ± 13.2 | 142.9 ± 17.6/78.0 ± 10.1 | 142.4 ± 18.3/77.7 ± 11.2 | 0.7/0.7 |
| Pre-HD weight, kg | 82.8 ± 16.7 | 82.2 ± 20.0 | 82.4 ± 18.8 | 0.9 |
| Post-HD weight, kg | 80.0 ± 16.1 | 79.2 ± 19.2 | 79.5 ± 18.1 | 0.8 |
| BMI | 26.7 ± 5.9 | 26.8 ± 5.7 | 26.7 ± 5.7 | 0.9 |
| Years on dialysis | 4.3 ± 6.0 | 3.6 ± 4.2 | 3.9 ± 4.9 | 0.5 |
| Etiology of ESRD | 0.7 | |||
| Diabetes mellitus | 15 (38) | 31 (42) | 46 (41) | |
| Hypertension | 18 (46) | 31 (42) | 49 (43) | |
| Glomerulonephritis | 2 (5) | 3 (4) | 5 (4) | |
| Polycystic kidney disease | 0 | 3 (4) | 3 (3) | |
| Other | 4 (10) | 6 (8) | 10 (9) | |
| Current smoker | 15 (38) | 23 (31) | 38 (34) | 0.4 |
| History of | ||||
| Congestive heart failure | 4 (10) | 15 (20) | 19 (17) | 0.2 |
| Myocardial infarction | 6 (15) | 13 (18) | 19 (17) | 0.8 |
| Stroke | 4 (10) | 7 (9) | 11 (10) | 0.9 |
| Urea reduction ratio, % | 73.0 ± 6.3 | 74.2 ± 7.4 | 73.8 ± 7.0 | 0.4 |
| Albumin, g/dl | 3.8 ± 0.4 | 3.7 ± 0.5 | 3.7 ± 0.5 | 0.9 |
| Hemoglobin, g/dl | 12.1 ± 1.4 | 12.2 ± 1.1 | 12.2 ± 1.2 | 0.7 |
| Presence of pedal edema | 7 (18) | 16 (22) | 23 (20) | 0.6 |
| Number receiving antihypertensive drugs | 29 (74) | 63 (85) | 92 (81) | 0.2 |
| Number of antihypertensives in users | 2.1 ± 1.7 | 2.2 ± 1.6 | 2.1 ± 1.6 | 0.8 |
| Dihydropyridine calcium channel blockers | 16 (41) | 33 (45) | 49 (43) | 0.7 |
| Nondihydropyridine calcium channel blockers | 2 (5) | 4 (5) | 6 (5) | 0.9 |
| β-Blockers | 25 (64) | 50 (68) | 75 (66) | 0.7 |
| α-Blockers | 3 (8) | 5 (7) | 8 (7) | 0.9 |
| Centrally acting agents | 8 (21) | 21 (28) | 29 (26) | 0.4 |
| Vasodilators | 9 (23) | 10 (14) | 19 (17) | 0.2 |
| ACE inhibitors | 20 (51) | 38 (51) | 58 (51) | 1 |
| Angiotensin receptor blockers | 4 (10) | 14 (19) | 18 (16) | 0.2 |
Figures in parentheses represent percentages. HD = Hemodialysis; SBP = systolic blood pressure; ESRD = end-stage renal disease.